Medical News

[ Headaches Are Common In Year Following Traumatic Brain Injury, Especially Among Females ]

Headaches Are Common In Year Following Traumatic Brain Injury, Especially Among Females

Recurring headaches are common during the year following a traumatic brain injury (TBI), regardless of the severity of the TBI, and they tend to occur more often among females and those with a pre-TBI history of headache, according to an article in Journal of Neurotrauma, a peer-reviewed journal published by Mary Ann Liebert, Inc. The article is available free online at the link below. More than 70% of patients who had suffered a TBI reported having headaches during the first year after their injury. This finding is a result of a multi-center study described by Jeanne Hoffman, PhD, Department of Rehabilitation Medicine, University of Washington, Seattle, and a group of colleagues from University of Washington, Craig Hospital (Denver, CO), Mayo Clinic (Rochester, MN), University of Alabama at Birmingham, University of Texas Southwestern Medical School (Dallas), Virginia Commonwealth University (Richmond), and Moss Rehab (Philadelphia, PA).

CoLucid Pharmaceuticals Receives Clearance For Investigational New Drug IND Application For Lasmiditan For The Treatment Of Acute Migraine

CoLucid Pharmaceuticals, Inc., a privately held biopharmaceutical company, announced that it has received clearance to proceed with clinical studies of lasmiditan (formerly known as COL-144) under IND 103, 420 from the Food and Drug Administration (FDA). Lasmiditan is a first-in-class oral tablet formulation of a Neurally Acting Anti-Migraine Agent (NAAMA) designed to deliver efficacy in migraine without the vasoconstrictor activity associated with previous generations of migraine therapies. Lasmiditan is a member of a novel chemical class called "ditans", and, unlike triptans, which target vasoconstrictor 5-HT1B receptors, lasmiditan penetrates the central nervous system (CNS) and selectively targets 5-HT1F receptors expressed in the trigeminal nerve pathway. Five clinical studies have been successfully completed outside of the U.

New Study Finds Images Placed In Front Of Smartphone Screen Increase Visual Discomfort

Several reports indicate that prolonged viewing of mobile devices and other stereo 3D devices leads to visual discomfort, fatigue and even headaches. According to a new Journal of Vision study, the root cause may be the demand on our eyes to focus on the screen and simultaneously adjust to the distance of the content. Scientifically referred to as vergence-accommodation, this conflict and its effect on viewers of stereo 3D displays are detailed in a recent Journal of Vision article, The Zone of Comfort: Predicting Visual Discomfort with Stereo Displays. "When watching stereo 3D displays, the eyes must focus - that is, accommodate - to the distance of the screen because that's where the light comes from. At the same time, the eyes must converge to the distance of the stereo content, which may be in front of or behind the screen, " explains author Martin S.

Multiple Migraine Attacks - Promising Results For SUMAVEL DosePro Phase 4 Clinical Trial

The publication of SUMAVEL DosePro (sumatriptan injection) Needle-free Delivery system Phase 4 clinical study results were announced by Zogenix, Inc., a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain. SAMUVEL was found to be an important treatment option for those with rapid-onset migraine attacks. Headache, The Journal of Head and Face Pain is the official publication of the American Headache Society (AHS). In the journal, authors reported that patients who currently use triptan in the treatment of multiple migraine attacks reported a higher level of satisfaction, confidence and preference for SUMAVEL DosePro. The publication, "Satisfaction With and Confidence in Needle-Free Subcutaneous Sumatriptan in Patients Currently Treated with Triptans, " is currently available online on the journal's website.

Tylenol Maximum Daily Dosage To Drop To 3,000mg Per Day From 4,000mg

Tylenol, whose active ingredient is acetaminophen, will now have a lower recommended daily dose, which is aimed at reducing the risk of accidental overdose, McNeil Consumer Healthcare, a Johnson & Johnson company announced today. The recommended daily maximum for Extra Strength Tylenol 500mg tablets will go down from 8 per day to 6 per day, i.e. from 4, 000mg per day to 3, 000mg per day. Acetaminophen, which is also known as paracetamol, is a commonly used OTC (over-the-counter) pain reliever (analgesic) and fever reducer (antipyretic). People use it for headaches, and minor aches and pain. It can be found in various cold and flu medications. Acetaminophen can also be used for more severe pain when used in combination with opioid analgesics. Acetaminophen can be found in over 600 OTC and prescription drugs, including Vicodin, Percocet, NyQuil, and Tylenol.

Fast: [10]

Medical News © Nanda
Designer Damodar